These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 38720446)
1. Immunotherapy Combining Mimotopes Selected by Phage Display Plus Amphotericin B Is Effective for Treatment Against Visceral Leishmaniasis. Soyer TG; Bandeira Câmara RS; Pereira IAG; Ramos FF; de Jesus MM; Ludolf F; de Paula Costa G; Lage DP; de Freitas CS; Vale DL; Pimenta BL; Martins VT; Galdino AS; Chávez-Fumagalli MA; Roatt BM; de Sousa Vieira Tavares G; Coelho EAF Parasite Immunol; 2024 May; 46(5):e13037. PubMed ID: 38720446 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with Soyer TG; Ramos FF; Pereira IAG; Lage DP; Bandeira RS; de Jesus MM; Costa GP; Machado AS; Freitas CS; Vale DL; Martins VT; Galdino AS; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Roatt BM; Coelho EAF; Tavares GSV Pathogens; 2023 Feb; 12(2):. PubMed ID: 36839586 [No Abstract] [Full Text] [Related]
3. Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system. Duarte MC; Lage LM; Lage DP; Martins VT; Carvalho AM; Roatt BM; Menezes-Souza D; Tavares CA; Alves RJ; Barichello JM; Coelho EA Parasitol Int; 2016 Dec; 65(6 Pt A):728-736. PubMed ID: 27425599 [TBL] [Abstract][Full Text] [Related]
4. A Pluronic® F127-based polymeric micelle system containing an antileishmanial molecule is immunotherapeutic and effective in the treatment against Leishmania amazonensis infection. Tavares GSV; Mendonça DVC; Miyazaki CK; Lage DP; Soyer TG; Carvalho LM; Ottoni FM; Dias DS; Ribeiro PAF; Antinarelli LMR; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF Parasitol Int; 2019 Feb; 68(1):63-72. PubMed ID: 30339837 [TBL] [Abstract][Full Text] [Related]
5. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis. Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446 [TBL] [Abstract][Full Text] [Related]
6. The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice. Lage DP; Martins VT; Vale DL; Freitas CS; Pimenta BL; Moreira GJL; Ramos FF; Pereira IAG; Bandeira RS; de Jesus MM; Ludolf F; Tavares GSV; Chávez-Fumagalli MA; Roatt BM; Christodoulides M; Coelho EAF Acta Trop; 2023 Oct; 246():106986. PubMed ID: 37453579 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis. Vale DL; Freitas CS; Martins VT; Moreira GJL; Machado AS; Ramos FF; Pereira IAG; Bandeira RS; de Jesus MM; Tavares GSV; Ludolf F; Chávez-Fumagalli MA; Galdino AS; Fujiwara RT; Bueno LL; Roatt BM; Christodoulides M; Coelho EAF; Lage DP Biology (Basel); 2023 Jun; 12(6):. PubMed ID: 37372136 [TBL] [Abstract][Full Text] [Related]
8. Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis. Reis TAR; Oliveira-da-Silva JA; Tavares GSV; Mendonça DVC; Freitas CS; Costa RR; Lage DP; Martins VT; Machado AS; Ramos FF; Silva AM; Ludolf F; Antinarelli LMR; Brito RCF; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Coimbra ES; Coelho EAF Exp Parasitol; 2021 Feb; 221():108059. PubMed ID: 33338468 [TBL] [Abstract][Full Text] [Related]
9. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453 [TBL] [Abstract][Full Text] [Related]
12. Selection strategy of phage-displayed immunogens based on an in vitro evaluation of the Th1 response of PBMCs and their potential use as a vaccine against Leishmania infantum infection. Ramos FF; Costa LE; Dias DS; Santos TTO; Rodrigues MR; Lage DP; Salles BCS; Martins VT; Ribeiro PAF; Chávez-Fumagalli MA; Dias ACS; Alves PT; Vieira ÉLM; Roatt BM; Menezes-Souza D; Duarte MC; Teixeira AL; Goulart LR; Coelho EAF Parasit Vectors; 2017 Dec; 10(1):617. PubMed ID: 29268793 [TBL] [Abstract][Full Text] [Related]
13. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166 [TBL] [Abstract][Full Text] [Related]
14. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis. Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species. Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571 [TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis. Freitas CS; Santiago SS; Lage DP; Antinarelli LMR; Oliveira FM; Vale DL; Martins VT; Magalhaes LND; Bandeira RS; Ramos FF; Pereira IAG; de Jesus MM; Ludolf F; Tavares GSV; Costa AV; Ferreira RS; Coimbra ES; Teixeira RR; Coelho EAF Exp Parasitol; 2023 Aug; 251():108555. PubMed ID: 37247802 [TBL] [Abstract][Full Text] [Related]
17. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans. Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740 [TBL] [Abstract][Full Text] [Related]